Literature DB >> 31851002

Revision of Pancreatic Neck Margins Based on Intraoperative Frozen Section Analysis Is Associated With Improved Survival in Patients Undergoing Pancreatectomy for Ductal Adenocarcinoma.

Biqi Zhang1, Grace C Lee1, Motaz Qadan1, Zhi Ven Fong1, Mari Mino-Kenudson2, Vikram Desphande2, Giuseppe Malleo3, Laura Maggino3, Giovanni Marchegiani3, Roberto Salvia3, Aldo Scarpa4,5, Claudio Luchini5, Lucia De Gregorio6, Cristina R Ferrone1, Andrew L Warshaw1, Keith D Lillemoe1, Claudio Bassi3, Carlos Fernández-Del Castillo1.   

Abstract

OBJECTIVE: To test the hypothesis that complete, tumor-free resection at the pancreatic neck, achieved either en-bloc or non-en-bloc (ie, revision based on intraoperative frozen section [FS] analysis), is associated with improved survival as compared with incomplete resection (IR) in pancreatic ductal adenocarcinoma. SUMMARY BACKGROUND DATA: Given the likely systemic nature of pancreatic ductal adenocarcinoma, the oncologic benefit of achieving a histologically complete local resection, particularly through revision of a positive intraoperative FS at the pancreatic neck, remains controversial.
METHODS: Clinicopathologic and treatment data were reviewed for 986 consecutive patients with ductal adenocarcinoma at the head, neck, or uncinate process of the pancreas who underwent open pancreatectomy as well as intraoperative FS analysis between 1998 and 2012 at Massachusetts General Hospital and between 1998 and 2013 at the University of Verona. Overall survival (OS) and perioperative morbidity and mortality were compared across 3 groups: complete resection achieved en-bloc (CR-EB), complete resection achieved non-en-bloc (CR-NEB), and IR.
RESULTS: The CR-EB cohort comprised 749 (76%) patients, CR-NEB 159 patients (16%), and IR 78 patients (8%). Other than a higher incidence of vascular resection among CR-NEB and IR patients, no demographic, pathologic (eg, tumor grade, lymph node positivity, superior mesenteric artery involvement), or treatment factors (eg, neoadjuvant and adjuvant therapy use) differed between the groups. Median OS was significantly higher in patients with CR-EB (28 mo, P = 0.01) and CR-NEB resections (24 mo, P = 0.02) as compared with patients with IR resections (19 mo). After adjusting for clinicopathologic and treatment characteristics, CR-EB and CR-NEB margin status were found to be independent predictors of improved OS (relative to IR, CR-EB hazard ratio [HR] 0.65, 95% confidence interval [CI] 0.49-0.86; CR-NEB HR 0.69, 95% CI 0.50-0.96). There were no intergroup differences in perioperative morbidity and mortality, including rates of pancreatic fistula.
CONCLUSIONS: For patients with ductal adenocarcinoma at the head, neck, or uncinate process of the pancreas undergoing pancreatectomy, complete tumor extirpation via either en-bloc or non-en-bloc complete resection based on FS analysis is associated with improved OS, without an associated increased perioperative morbidity or mortality.
Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 31851002     DOI: 10.1097/SLA.0000000000003503

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  10 in total

1.  Prospective randomized controlled study for comparison of 2-dimensional versus 3-dimensional laparoscopic distal gastrectomy for gastric adenocarcinoma.

Authors:  Kanghaeng Lee; Sang Il Youn; Yongjoon Won; Sa-Hong Min; Young Suk Park; Sang-Hoon Ahn; Do Joong Park; Hyung-Ho Kim
Journal:  Surg Endosc       Date:  2020-04-30       Impact factor: 4.584

2.  Micronvasive behaviour of single small hepatocellular carcinoma: which treatment?

Authors:  Roberto Santambrogio; Matteo Barabino; Valentina D'Alessandro; Giulio Iacob; Enrico Opocher; Marco Gemma; Marco Antonio Zappa
Journal:  Updates Surg       Date:  2021-04-05

3.  Positive pancreatic neck margins-a telltale sign of complex biology.

Authors:  Elie Ghabi; Jin He
Journal:  Hepatobiliary Surg Nutr       Date:  2022-04       Impact factor: 7.293

4.  ASO Author Reflections: Pancreatic Resection Margins-Chasing Moons.

Authors:  Mihir M Shah; Jashodeep Datta; Nipun B Merchant; David A Kooby
Journal:  Ann Surg Oncol       Date:  2022-01-07       Impact factor: 5.344

5.  Landmark Series: Importance of Pancreatic Resection Margins.

Authors:  Mihir M Shah; Jashodeep Datta; Nipun B Merchant; David A Kooby
Journal:  Ann Surg Oncol       Date:  2022-01-05       Impact factor: 5.344

Review 6.  [Surgical treatment of pancreatic cancer-What is new?]

Authors:  Thomas Schmidt; Orlin Belyaev; Waldemar Uhl; Christiane J Bruns
Journal:  Chirurg       Date:  2022-03-31       Impact factor: 0.955

7.  Impact of Neoadjuvant Therapy on Minimally Invasive Surgical Outcomes in Advanced Gastric Cancer: An International Propensity Score-Matched Study.

Authors:  Yongjia Yan; Annie Yang; Li Lu; Zhicheng Zhao; Chuan Li; Weidong Li; Joseph Chao; Tong Liu; Yuman Fong; Weihua Fu; Yanghee Woo
Journal:  Ann Surg Oncol       Date:  2020-08-29       Impact factor: 5.344

8.  Impact of intraoperative margin clearance on survival following pancreatoduodenectomy for pancreatic cancer: a systematic review and meta-analysis.

Authors:  Emrullah Birgin; Erik Rasbach; Patrick Téoule; Felix Rückert; Christoph Reissfelder; Nuh N Rahbari
Journal:  Sci Rep       Date:  2020-12-17       Impact factor: 4.379

9.  Neoadjuvant therapy is associated with lower margin positivity rates after Pancreaticoduodenectomy in T1 and T2 pancreatic head cancers: An analysis of the National Cancer Database.

Authors:  Stephanie H Greco; David A August; Mihir M Shah; Chunxia Chen; Dirk F Moore; Monika Masanam; Amber L Turner; Salma K Jabbour; Parisa Javidian; Miral S Grandhi; Timothy J Kennedy; H Richard Alexander; Darren R Carpizo; Russell C Langan
Journal:  Surg Open Sci       Date:  2020-12-16

Review 10.  Malignant epithelial/exocrine tumors of the pancreas.

Authors:  Claudio Luchini; Federica Grillo; Matteo Fassan; Alessandro Vanoli; Paola Capelli; Gaetano Paolino; Giuseppe Ingravallo; Giuseppina Renzulli; Claudio Doglioni; Alessandro D'Amuri; Paola Mattiolo; Sara Pecori; Paola Parente; Ada M Florena; Giuseppe Zamboni; Aldo Scarpa
Journal:  Pathologica       Date:  2020-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.